Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 7/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028485 | 0.90 | KMO (0.46) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028481 | 0.90 | KMO (0.46) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028199 | 0.89 | KMO (0.46) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028231 | 0.89 | KMO (0.46) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028206 | 0.87 | KMO (0.44) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028201 | 0.87 | KMO (0.48) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028207 | 0.86 | KMO (0.42) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028196 | 0.86 | KMO (0.43) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028391 | 0.86 | KMO (0.43) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14541180 | 0.86 | KMO (0.43) | KMOCNR2CDK4CCND3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-6630497-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO | 2003-10-07 | — | — | US | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. | 2002-03-28 | — | — | US | disclosed |
| EP-0690854-B1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0978515-A2 | 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038035-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | KMO 408/4885CNR2 221/4885CDK4 2442/4885 |
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | KMO 716/4885CNR2 462/4885CDK4 2063/4885 |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | KMO 2307/4885CNR2 2418/4885CDK4 692/4885 |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | KMO 408/4885CNR2 221/4885CDK4 2442/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | KMO 2307/4885CNR2 2418/4885CDK4 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.